Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) announced acceptance of a late-breaking oral presentation of data from its RestorAATion-2 trial of WVE-006 for alpha-1 antitrypsin deficiency at the American Thoracic Society International Conference, May 15-20, 2026 in Orlando.

The presentation will include new data from the 400 mg multidose cohort and the 600 mg single dose cohort, and is scheduled for May 18, 2026 at 4:03 p.m. ET. The company expects regulatory feedback on a potential accelerated approval pathway for WVE-006 mid-2026 and said INLIGHT trial data for WVE-007 is expected this month.

News Market Reaction – WVE

-3.72%

1 alert

-3.72% News Effect

On the day this news was published, WVE declined 3.72%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

RestorAATion-2 dose: 400 mg RestorAATion-2 dose: 600 mg ATS conference dates: May 15–20, 2026 +1 more

4 metrics

RestorAATion-2 dose 400 mg Multidose cohort data to be presented at ATS

RestorAATion-2 dose 600 mg Single dose cohort data to be presented at ATS

ATS conference dates May 15–20, 2026 American Thoracic Society International Conference window

Presentation time 4:03–4:15 p.m. ET Late-breaking oral presentation on May 18, 2026

Market Reality Check

Price: $13.20 Vol: Volume 1,277,175 vs 20-da...

low vol

$13.20 Last Close

Volume Volume 1,277,175 vs 20-day average 2,506,099 (relative volume 0.51), suggesting subdued trading ahead of the conference data. low

Technical Price 13.71 is trading above the 200-day MA at 9.72, with shares up 2.01% pre-announcement.

Peers on Argus

WVE gained 2.01% while only one momentum-scanner peer (AMLX) appeared, up 3.65%,...

1 Up

WVE gained 2.01% while only one momentum-scanner peer (AMLX) appeared, up 3.65%, and no other tracked peers show coordinated moves. This points to a company-specific reaction to the AATD trial presentation news rather than a sector-wide biotech rotation.

Historical Context

5 past events · Latest: Feb 26 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Earnings and update	Neutral	+5.6%	Q4 and 2025 results plus pipeline updates and cash runway into 3Q 2028.
Feb 23	Conference appearance	Neutral	+0.1%	CEO fireside chat at Oppenheimer healthcare conference with webcast access.
Feb 19	Earnings scheduling	Neutral	+0.5%	Announcement of date and time for Q4 and full-year 2025 earnings call.
Feb 02	Program rights and plans	Positive	+3.8%	Regained full rights to WVE-006 and outlined accelerated approval strategy.
Jan 12	Strategic pipeline update	Positive	+0.5%	Set 2026 priorities, highlighting WVE-007 obesity program and RNA editing portfolio.

Pattern Detected

Recent WVE news around pipeline and strategy, including WVE-006 and WVE-007 updates, has typically seen modestly positive share reactions, especially when paired with strong cash runway disclosures.

Recent Company History

Over the last few months, Wave Life Sciences has highlighted its RNA medicines pipeline and financial runway. On Jan 12, 2026, it outlined 2026 priorities, emphasizing WVE-007 obesity data and RNA editing progress. On Feb 2, 2026, it regained full rights to WVE-006 and advanced plans for an accelerated approval pathway in AATD. Earnings and 10-K related updates on Feb 26, 2026 reinforced a cash runway into 3Q 2028. Today’s ATS late-breaking presentation acceptance for RestorAATion-2 data extends that same WVE-006 narrative.

Market Pulse Summary

This announcement adds specificity to the WVE-006 story by confirming late-breaking oral presentatio...

Analysis

This announcement adds specificity to the WVE-006 story by confirming late-breaking oral presentation status and inclusion of both 400 mg multidose and 600 mg single-dose RestorAATion-2 data at ATS in mid-2026. It follows recent disclosures on accelerated approval discussions and a cash runway into 3Q 2028. Investors may watch how these data complement prior AATD updates and interact with parallel progress in the WVE-007 obesity program.

Key Terms

galnac-rna editing, rna editing, alpha-1 antitrypsin deficiency, aatd, +4 more

8 terms

galnac-rna editing medical

"RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data"

GalNAc-RNA editing is a therapeutic approach that uses a sugar-based delivery tag (GalNAc) to carry molecular tools into liver cells and alter a target RNA’s message so the cell makes a different protein. Think of GalNAc as a postal label that ensures the editing kit reaches the liver, and RNA editing as rewriting a sentence inside a book so the cell reads a corrected instruction. It matters to investors because successful delivery and precise editing can create drugs for genetic or metabolic liver diseases with potentially large markets and clearer regulatory paths than permanent DNA changes.

rna editing medical

"well suited for RNA editing because it is a single‑gene disorder"

RNA editing is a natural or engineered process that changes the molecular message copied from a gene before it is used to make a protein, like tweaking a recipe after it’s written to alter the final dish. For investors, RNA editing matters because it enables new kinds of medicines and diagnostics — promising bigger returns but also carrying technical, safety and regulatory risks that can strongly affect a biotech company’s value.

alpha-1 antitrypsin deficiency medical

"for alpha-1 antitrypsin deficiency (AATD), at the upcoming American Thoracic"

A genetic condition in which the body makes too little of a protective protein called alpha‑1 antitrypsin, leaving lungs and sometimes the liver vulnerable to damage; imagine a car missing some brake pads so wear and tear accelerates. It matters to investors because the condition defines a specific patient population, shapes demand for diagnostics and therapies, and concentrates regulatory, clinical trial and reimbursement risks and opportunities for companies developing treatments.

aatd medical

"for alpha-1 antitrypsin deficiency (AATD), at the upcoming American Thoracic"

Alpha-1 antitrypsin deficiency (AATD) is a inherited condition in which the body makes too little of a protein that protects the lungs and liver, leaving those organs vulnerable to damage over time. For investors, AATD matters because it creates a defined patient group and clear clinical needs—like a broken brake in a car—so diagnostics, replacement therapies, or gene treatments targeting AATD can represent focused markets, regulatory pathways, and long-term revenue potential.

oligonucleotide medical

"RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD)"

A short chain of DNA or RNA molecules used to target, detect, or change specific genetic messages inside cells; think of it as a tiny, programmable instruction or zip code that can find and bind one exact genetic sentence. Investors care because oligonucleotides are the active ingredient in a growing class of precision therapies and diagnostics, so their success, manufacturing cost, and regulatory approval can directly affect a company's value and future revenue.

accelerated approval pathway regulatory

"advancing regulatory engagement on a potential accelerated approval pathway for WVE-006"

The accelerated approval pathway is a process that allows new medicines to be approved more quickly based on early evidence that they may be effective, rather than waiting for full proof. This can help patients access promising treatments faster, but it also means ongoing studies are needed to confirm the benefits. For investors, it highlights potential faster market entry and earlier revenue opportunities, along with some uncertainty about long-term outcomes.

biomarkers medical

"Session: B101 Decoding Disease: Biomarkers, Phenotypes, and Precision Medicine"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

precision medicine medical

"Session: B101 Decoding Disease: Biomarkers, Phenotypes, and Precision Medicine"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

AI-generated analysis. Not financial advice.

Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference

CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced acceptance of a late-breaking oral presentation of data from its ongoing RestorAATion-2 clinical trial of WVE-006, its investigational GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), at the upcoming American Thoracic Society (ATS) International Conference taking place in Orlando, Florida during May 15-20, 2026. Wave now expects to share data from the 600 mg single dose cohort in addition to data from the 400 mg multidose cohort at the ATS conference in May.

“The annual ATS conference is an important forum for fostering innovation in pulmonary care, and we are excited to have the opportunity to share data from our RestorAATion-2 trial, including our upcoming 400 mg multidose data and 600 mg single dose data,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. “AATD, a debilitating disease that impacts many aspects of daily life, is well suited for RNA editing because it is a single‑gene disorder, where correcting the mutant RNA transcript in the liver directly addresses the root cause of both lung and liver manifestations of the disease. We are advancing regulatory engagement on a potential accelerated approval pathway for WVE-006 and expect feedback mid-2026. Additionally, we remain on track to deliver data from the INLIGHT trial of WVE-007 for obesity this month.”

Details of the late-breaking oral presentation:
Title: RNA Editing for the Treatment of Alpha-1 Antitrypsin Deficiency
Session: B101 Decoding Disease: Biomarkers, Phenotypes, and Precision Medicine
Presenter: Kenneth R. Chapman, MsC, MD, FRCPC, FACP, FERS, Department of Medicine, University of Toronto
Date and time: Monday, May 18, 2026, 4:03 – 4:15 p.m. ET

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated initiation, timing, design, progress, data and announcements related to our clinical trials, including interactions with and feedback from regulators and any potential registrational submissions based on these data; the future performance and results of our programs in clinical trials, including the anticipated therapeutic benefits of such programs and our expectations with respect to how our clinical data may predict success for our future therapeutic candidates and data readouts; the breadth and versatility of our PRISM^® drug discovery and development platform; and the potential benefits of our RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers). The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. Actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings we make with the SEC from time to time. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation, except to the extent required by law, to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

FAQ

What will Wave (WVE) present about WVE-006 at the ATS conference on May 18, 2026?

Wave will present new RestorAATion-2 data from the 400 mg multidose and 600 mg single dose cohorts. According to the company, this is a late-breaking oral presentation on RNA editing for AATD, scheduled for May 18, 2026 at 4:03 p.m. ET in Orlando.

How does the May 2026 ATS presentation impact WVE-006 regulatory plans for WVE (WVE)?

The ATS presentation advances clinical visibility ahead of regulatory engagement for WVE-006. According to the company, Wave is pursuing feedback on a potential accelerated approval pathway and expects regulatory feedback mid-2026 following additional cohort data disclosure.

Which cohorts from RestorAATion-2 will Wave (WVE) share at ATS May 2026?

Wave will share data from the 400 mg multidose cohort and the 600 mg single dose cohort. According to the company, both cohorts' results will be presented in the late-breaking oral session on May 18, 2026.

Who is presenting Wave's (WVE) WVE-006 data at the ATS International Conference?

Kenneth R. Chapman, MD, from the University of Toronto, will present the WVE-006 late-breaking oral session. According to the company, the presentation is titled "RNA Editing for the Treatment of Alpha-1 Antitrypsin Deficiency."

Will Wave (WVE) provide other trial updates around the ATS presentation in May 2026?

Yes; Wave said it remains on track to deliver INLIGHT trial data for WVE-007 for obesity this month. According to the company, the INLIGHT data release is expected prior to the mid-2026 regulatory feedback milestone for WVE-006.